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UnOBJECTIVES This study sought to clarify the clinical and echocardiographic prognostic implication of myocardial injury
after transcatheter aortic valve replacement (TAVR).
BACKGROUND The clinical signiﬁcance of cardiac biomarker elevation after TAVR remains unclear.
METHODS Patients treated with TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) trial were divided
into tertiles (T1, T2, T3) based on the difference between the values on post-procedure day 1 and the baseline values of
2 cardiac biomarkers: cardiac troponin I (DcTnI); and creatine kinase-myocardial band (DCK-MB) fraction. Patients were
stratiﬁed according to their access route: transfemoral (TF) (n ¼ 1,840) or transapical (TA) (n ¼ 1,173).
RESULTS At 30 days after TF-TAVR, patients in the highest tertile (T3) of cardiac biomarker elevation had a higher rate
of all-cause mortality (DcTnI: T3: 5.4% vs. T1: 0.5%, p ¼ 0.006; DCK-MB: T3: 5.7% vs. T1: 0.9%, p ¼ 0.006) and
cardiovascular mortality (DcTnI: T3: 4.9% vs. T1: 0.5%, p ¼ 0.01; DCK-MB: T3: 3.9% vs. T1: 0.5%, p ¼ 0.02). At 1 year,
only patients in the highest CK-MB tertile had higher rates of all-cause (25.4% vs. 16.8%, p ¼ 0.02) and cardiovascular
(10.3% vs. 5.0%) mortality. Multivariable analysis demonstrated that greater release of cardiac biomarkers was inde-
pendently associated with increased mortality in the TF population. After TA-TAVR, being in the highest tertile of cardiac
biomarker elevation had no inﬂuence on clinical and echocardiographic outcomes at 30 days and 1 year.
CONCLUSIONS After TF-TAVR, a greater degree of myocardial injury was associated with higher rates of 30-day
all-cause and cardiovascular mortality. At 1 year, being in the highest tertile of DCK-MB was correlated with a higher rate
of all-cause and cardiac mortality. Finally, the level of myocardial injury after TA-TAVR had no impact on clinical and
echocardiographic outcomes. (J Am Coll Cardiol Intv 2015;8:1468–79) © 2015 by the American College of Cardiology
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1469AB BR E V I A T I O N S
AND ACRONYM S
AVR = aortic valve
replacement
CK-MB = creatine kinase-
myocardial band
cTnI = cardiac troponin I
LV = left ventricle
LVEF = left ventricular
ejection fraction
MI = myocardial infarction
NYHA = New York Heart
Association
TA = transapical
TAVR = transcatheter aortic
valve replacement
TF = transfemoralT ranscatheter aortic valve replacement (TAVR)has become the standard treatment option forinoperable patients with severe symptomatic
aortic stenosis (1,2) and has been shown to be nonin-
ferior to surgical AVR in terms of survival among
selected high-risk patients (3,4). Recent studies have
shown that a transapical (TA) approach to TAVR is asso-
ciated with some degree of myocardial injury, which is
exacerbated by renal dysfunction (5–7).
Myocardial injury after TAVR could be inﬂuenced
by procedural or patient-speciﬁc factors. Myocardial
damage following cardiac surgery or percutaneous
coronary intervention has been strongly associated
with cardiovascular morbidity and mortality (8–10);
however, the clinical signiﬁcance of cardiac bio-
marker elevation after TAVR remains uncertain.
Accordingly, we sought to better characterize the
clinical and echocardiographic impact of myocardial
damage after transfemoral (TF) and TA TAVR using
data from the multicenter PARTNER (Placement of
Aortic Transcatheter Valves) trial.
METHODS
STUDY POPULATION. The design and results of the
PARTNER trial (cohorts A and B) have been previ-
ously published (1–4). Brieﬂy, the randomized
portion of the trial enrolled patients with severe
symptomatic aortic stenosis who were either at high
risk for surgical AVR (cohort A) or deemed inoper-
able (cohort B). In cohort A, after assessment of
vascular anatomy, patients were allocated to a TF or
TA placement cohort and randomized to TAVR with
the Edwards Sapien heart valve system (Edwards
Lifesciences, Irvine, California) or surgical valve
replacement. In cohort B, patients were randomized
to standard therapy or TAVR via a TF approach if
vascular access was adequate. After completion offunded by Edwards Lifesciences and designed collaboratively by the steering
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domized Continued Access) registry allowed
treatment of both cohort A and cohort B
patients with TAVR. Inclusion and exclu-
sion criteria, data collection, and monitoring
were the same in both the randomized trial
and the NRCA registry. All patients were
presented and adjudicated as appropriate
candidates during conference calls with the
executive committee and other investigators.
For the current analysis, we included only
patients who were randomized to and treated
with TAVR in the randomized trial and those
treated with TAVR in the NRCA registry
(as-treated population) who had cardiac
biomarkers—cardiac troponin I (cTnI) and
creatinine kinase-myocardial band (CK-MB)
fraction—measured at baseline and on the
ﬁrst day after the procedure. Many centers used
several different immunoassays for measurements of
troponin and CK-MB. In order to have the largest
study group possible, but to limit variability and to
allow each patient to become his/her own control, we
elected to exclude patients with troponin T mea-
surements (because a minority of centers were using
this speciﬁc immunoassay). The PARTNER study was
approved by the institutional review board at each
participating site, and all patients provided written
informed consent.
CARDIAC BIOMARKERS. Patients were stratiﬁed
according to their access route (TF or TA). Cardiac
biomarkers were measured at baseline and on post-
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TABLE 1 Baseline Characteristics in the TF and the TA Groups
cTnI CK-MB
T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups) T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups)
Transfemoral
Age, yrs 83.0 85.3 85.1 0.006 0.004 83.0 84.4 84.5 0.054 0.10
Male 64.2 55.4 49.5 0.004 0.02 63.0 57.1 48.3 0.002 0.009
BMI, kg/m2 28.7 26.8 26.4 0.0005 0.002 27.6 26.7 26.4 0.04 0.10
STS score 10.4 11.5 11.1 0.08 0.02 10.6 11.5 11.2 0.19 0.11
Dyslipidemia 83.9 83.7 85.4 0.68 0.88 82.9 82.1 77.0 0.13 0.25
Hypertension 92.5 92.9 91.9 0.83 0.94 91.5 89.2 89.0 0.39 0.64
History of smoking 43.0 32.6 37.8 0.31 0.12 47.4 39.6 42.1 0.28 0.26
NYHA functional class III–IV 95.2 95.1 94.8 0.64 0.87 93.8 96.2 95.2 0.54 0.52
CAD 79.6 66.3 69.2 0.02 0.01 81.5 73.1 68.9 0.003 0.01
Previous PCI 40.8 28.3 33.5 0.15 0.04 42.9 31.3 29.7 0.005 0.008
Previous CABG 41.9 32.6 32.4 0.06 0.09 46.4 44.3 32.1 0.003 0.005
Diabetes 45.2 36.4 34.1 0.03 0.07 45.0 37.3 36.4 0.07 0.14
PVD 38.8 27.6 35.2 0.47 0.07 24.2 29.5 23.8 0.93 0.22
Cerebrovascular disease 22.0 23.0 18.5 0.39 0.54 26.9 22.5 16.4 0.009 0.03
Renal disease, creat $2 mg/dl 17.7 15.3 18.9 0.77 0.65 14.7 14.7 19.6 0.18 0.29
Liver disease 2.7 1.6 1.1 0.26 0.50 2.8 1.9 2.4 0.78 0.81
Atrial ﬁbrillation 25.7 19.8 18.8 0.11 0.22 18.6 21.0 15.4 0.39 0.34
COPD 49.2 46.7 36.0 0.01 0.02 46.9 47.6 44.5 0.62 0.80
Porcelain aorta 3.7 5.4 5.4 0.45 0.69 7.6 5.2 9.1 0.58 0.30
Transapical
Age, yrs 83.4 84.9 86.4 0.002 0.008 84.4 84.7 85.3 0.21 0.44
Male 67.3 45.6 43.4 0.0003 0.0004 55.8 46.0 36.0 0.0009 0.004
BMI, kg/m2 26.4 26.1 24.8 0.02 0.04 26.3 26.5 24.9 0.04 0.05
STS score 11.2 12.2 11.7 0.18 0.053 12.4 11.5 12.0 0.55 0.28
Dyslipidemia 89.4 88.6 85.8 0.42 0.69 89.9 84.9 82.0 0.06 0.17
Hypertension 97.3 94.7 98.2 0.65 0.30 99.3 98.6 96.4 0.10 0.19
History of smoking 59.3 47.4 44.2 0.02 0.058 52.2 55.4 50.7 0.21 0.18
NYHA functional class III–IV 94.7 93.9 93.8 0.78 0.95 93.5 98.6 94.2 0.79 0.09
CAD 80.4 84.2 76.1 0.44 0.45 85.4 78.4 74.1 0.02 0.07
Previous PCI 43.4 44.7 50.9 0.26 0.48 45.7 50.4 41.3 0.47 0.32
Previous CABG 58.4 47.4 34.5 0.0003 0.002 63.0 41.7 38.8 0.0001 0.0001
Diabetes 40.7 35.1 33.6 0.27 0.51 40.6 33.1 28.1 0.03 0.09
PVD 55.0 65.8 53.6 0.84 0.13 57.7 62.5 60.9 0.59 0.71
Cerebrovascular disease 22.3 32.5 16.8 0.30 0.02 27.7 26.8 23.0 0.37 0.64
Renal disease, creat $2 mg/dl 18.6 22.8 16.8 0.73 0.50 16.7 12.2 19.4 0.55 0.26
Liver disease 0.0 1.8 0.9 0.32 0.37 2.2 3.6 1.4 0.64 0.49
Atrial ﬁbrillation 30.4 26.5 20.4 0.08 0.22 22.6 24.6 16.8 0.22 0.26
COPD 47.8 51.8 34.5 0.04 0.02 42.8 47.5 43.2 0.94 0.68
Porcelain aorta 0 0 2.7 0.08 0.05 0.7 2.9 1.4 0.57 0.37
Values are percentages unless otherwise indicated.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CK-MB ¼ creatine kinase-myocardial band; COPD ¼ chronic obstructive
pulmonary disease; creat ¼ creatinine; cTnI ¼ cardiac troponin I; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular
disease; STS ¼ Society of Thoracic Surgeons; T ¼ tertile; TA ¼ transapical; TF ¼ transfemoral.
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each cardiac marker (DcTnI and DCK-MB).
STUDY ENDPOINTS. Study endpoints were reported
according to Valve Academic Research Consortium
deﬁnitions (11) or according to the deﬁnitions estab-
lished in the PARTNER 1 protocol. All adverse eventswere adjudicated by an independent clinical events
committee. Independent core laboratory analysis was
performed on all echocardiograms and electrocar-
diograms. All data were sent for analysis to an inde-
pendent academic biostatistics group.
Periprocedural myocardial infarction (MI) was
deﬁned according to a modiﬁed version of the Valve
TABLE 2 Baseline Procedural Characteristics for TF- and TA-TAVR Cases
cTnI CK-MB
T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups) T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups)
Transfemoral
Hemodynamic data
Mean RA pressure, mm Hg 12.1 10.9 11.0 0.11 0.16 12.5 12.6 11.4 0.16 0.22
Mean PA pressure, mm Hg 28.5 29.5 26.8 0.14 0.07 30.2 29.2 27.6 0.01 0.05
Cardiac index, l/min/m2 2.10 2.13 2.15 0.54 0.83 2.09 2.16 2.22 0.24 0.50
Mean AVA, cm2 0.68 0.62 0.69 0.98 0.41 0.65 0.60 0.62 0.31 0.056
Mean aortic gradient, mm Hg 37.7 38.4 44.3 0.0003 0.0004 37.2 37.4 41.5 0.009 0.01
Echocardiographic data
LVEF, % 50.3 51.9 55.7 <0.0001 0.0002 50.6 52.3 55.3 0.0003 0.001
AVA, cm2 0.67 0.68 0.65 0.29 0.33 0.67 0.66 0.65 0.42 0.71
Mean aortic gradient, mm Hg 39.5 43.3 47.7 <0.0001 <0.0001 41.4 42.3 47.3 <0.0001 <0.0001
Procedural data
Procedural time, min 113.1 124.5 134.7 0.004 0.01 125.4 125.1 141.7 0.02 0.02
Volume of contrast, ml 135.5 158.2 145.4 0.58 0.45 157.8 142.7 148.9 0.55 0.58
Prosthesis size
23 mm, % 51.6 53.3 61.2 0.07 0.15 47.6 51.7 57.6 0.04 0.12
26 mm, % 48.4 46.7 38.8 0.07 0.15 52.4 48.3 42.4 0.04 0.12
LM obstruction, % 0 0 0 N/A N/A 0 0 0 N/A N/A
Need for hemodynamic
support—CPB or IABP, %
2.1 2.2 2.7 0.72 0.92 0.5 1.4 1.9 0.18 0.41
Procedure success, % 76.5 77.2 71.0 0.23 0.32 82.0 76.9 72.2 0.02 0.06
Transapical
Hemodynamic data
Mean RA pressure, mm Hg 12.0 11.9 11.5 0.58 0.83 13.0 12.0 12.0 0.26 0.32
Mean PA pressure, mm Hg 29.4 29.2 28.7 0.63 0.88 29.86 28.15 29.14 0.71 0.38
Cardiac index, l/min/m2 2.30 2.23 2.09 0.10 0.24 2.31 2.10 2.14 0.09 0.09
Mean AVA, cm2 0.61 0.59 0.63 0.72 0.62 0.62 0.62 0.59 0.34 0.92
Mean aortic gradient, mm Hg 37.3 40.6 40.8 0.21 0.35 35.39 39.47 39.61 0.07 0.13
Echocardiographic data
LVEF, % 51.0 53.0 53.0 0.23 0.37 48.6 53.4 55.5 0.0001 0.0001
AVA, cm2 0.67 0.64 0.63 0.08 0.21 0.65 0.65 0.63 0.43 0.73
Mean aortic gradient, mm Hg 42.3 43.6 43.8 0.52 0.80 39.9 42.6 42.4 0.003 0.01
Procedural data
Procedural time, min 107.6 116.6 119.6 0.16 0.33 122.7 115.6 119.7 0.68 0.61
Volume of contrast, ml 108.7 117.0 103.9 0.66 0.47 100.4 120.9 114.0 0.12 0.055
Prosthesis size
23 mm, % 34.5 49.6 66.1 <0.0001 <0.0001 48.9 46.7 64.2 0.01 0.007
26 mm, % 65.5 50.4 33.9 <0.0001 <0.0001 51.1 53.3 35.8 0.01 0.007
LM obstruction, % 0 0 0 N/A N/A 0 0 0.72 N/A N/A
Need for hemodynamic
support—CPB or IABP, %
15.9 17.5 17.7 0.72 0.93 21.0 11.5 16.5 0.34 0.10
Procedure success, % 85.0 84.2 75.2 0.07 0.11 77.5 82.7 70.5 0.18 0.052
AVA ¼ aortic valve area; CBP ¼ cardiopulmonary bypass; IABP ¼ intra-aortic balloon pump; LM ¼ left main; LVEF ¼ left ventricular ejection fraction; N/A ¼ not available;
PA ¼ pulmonary artery; RA ¼ radial artery; TAVR ¼ transcatheter aortic valve replacement; other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5 Paradis et al.
S E P T E M B E R 2 0 1 5 : 1 4 6 8 – 7 9 Myocardial Injury After TAVR
1471Academic Research Consortium criteria (12) as
described in the PARTNER trial protocol (1–4). Any of
the following criteria met the deﬁnition of MI:
1) acute MI demonstrated by autopsy; 2) emergent
percutaneous coronary intervention performed for
acute ST-segment elevation myocardial infarction;
3) administration of thrombolytics for acute MI;4) clinical periprocedural MI (up through 7 complete
days post–index procedure) deﬁned as follows:
a. periprocedural Q-wave MI: development of new
pathologic Q waves in 2 or more contiguous leads
with elevation of CK-MB or CK (in absence of
CK-MB data). New Q waves in the absence of
FIGURE 1 All-Cause and Cardiovascular Mortality After TF-TAVR
30-day (A) and 1-year (B) all-cause and cardiovascular mortality rates after transfemoral transcatheter aortic valve replacement (TF-TAVR), stratiﬁed by cardiac enzyme
tertiles (T). CK-MB ¼ creatine kinase-myocardial band; cTnI ¼ cardiac troponin I.
Continued on the next page
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1472symptoms or elevated markers were not consid-
ered an MI; and
b. periprocedural non–Q-wave MI: documented signs
or symptoms of ischemia and/or new ischemic
changes on electrocardiography and CK-MB ele-
vation >10 the upper limit of normal. In the
absence of CK-MB data, CK was used with the same
>10 the upper limit of normal criteria.
STATISTICAL ANALYSIS. Continuous variables were
analyzed via mean  SD or medians and quartiles, as
appropriate, and were compared using Student t test.
If data were not normally distributed, the Mann-Whitney U test was used instead. Categorical vari-
ables were analyzed with the chi-square test or Fisher
exact test where asymptotic validity was not met. For
each access route (TF vs. TA), clinical and echocar-
diographic outcomes were compared across tertiles
and between the highest and lowest tertiles (T3 and
T1). Kaplan-Meier estimates were used to construct
survival curves for time-to-event variables, which
were compared using the log-rank test. Statistical
signiﬁcance was deﬁned as a p value <0.05. Uni-
variable analysis and multivariable logistic regression
were performed to identify independent predictors
of 30-day and 1-year all-cause mortality and
FIGURE 1 Continued
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1473cardiovascular mortality, respectively. To avoid
overﬁtting, variables included in the multivariable
model were selected only if they were of clinical in-
terest and/or fulﬁlled the entry criterion of p < 0.1 in
the univariable analysis. We also used cubic spline
plots to display the estimated cubic spline function
relating DcTnI and DCK-MB to the 30-day and 1-year
all-cause mortality for a Cox model (Online
Appendix). Data are based on an extract date of
March 11, 2014. All statistical analyses were performed
with the use of SAS software (version 9.2, SAS Insti-
tute, Cary, North Carolina).
FUNDING SOURCE. The PARTNER trial was funded by
Edwards Lifesciences and designed collaboratively
by the steering committee and the sponsor.The present analysis was carried out mainly by in-
vestigators at the Cardiovascular Research Foun-
dation, Columbia University Medical Center, and
Washington University School of Medicine. The au-
thors had unrestricted access to the study data, draf-
ted the manuscript, made the decision to submit for
publication, and guarantee the completeness and ac-
curacy of its content.RESULTS
PATIENTS AND BASELINE CHARACTERISTICS.
Among the 3,013 patients enrolled in the as-treated
population of the PARTNER trial, 1,840 were treated
with TAVR via the TF approach and 1,173 by a TA
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1474approach. In the TF population, 557 patients had cTnI
measurements at the 2 speciﬁed time points. Among
these patients, the DcTnI had the following distribu-
tion: T1 (n ¼ 187), 82.81 to 0.30 ng/ml; T2 (n ¼ 184),
0.31 to 0.88 ng/ml; and T3 (n ¼ 186), 0.89 to
402.38 ng/ml. DCK-MB data were available in 632
patients with the following distribution: T1 (n ¼ 211),
80.00 to 0.80 U/l; T2 (n ¼ 212), 0.90 to 2.90 U/l; and
T3 (n ¼ 209), 3.00 to 85.90 U/l. In the TA population,
DcTnI was available in 340 patients: T1 (n ¼ 113),
5.62 to 4.41 ng/ml; T2 (n ¼ 114), 4.42 to 8.09 ng/ml;
and T3 (n ¼ 113), 8.10 to 348.87 ng/ml. Also, among
the TA population, 416 were included in the DCK-MB
analysis with the following distribution: T1 (n ¼ 138),
27.00 to 9.40 U/l; T2 (n ¼ 139), 9.41 to 21.60 U/l; and
T3 (n ¼ 139), 21.61 to 4,027.00 U/l. Baseline and per-
iprocedural characteristics of patients stratiﬁed by
approach and further divided by tertiles for each
cardiac biomarker are shown in Table 1. Patients in
the highest tertiles of both biomarkers were more
commonly women and had a lower prevalence of
previous coronary artery bypass graft irrespective of
approach. The hemodynamic and echocardiographic
data are summarized in Table 2.
CLINICAL AND ECHOCARDIOGRAPHIC OUTCOMES.
Transfemoral approach . Mortality.When compared
with the lowest tertile (T1), patients in the highest ter-
tile (T3) of cardiac biomarker elevation who underwent
a TF approach had a higher rate of all-cause mortality
(DcTnI: T3: 5.4% vs. T1: 0.5%, p ¼ 0.006; DCK-MB: T3:
5.7% vs. T1: 0.9%, p ¼ 0.006) and cardiovascular
mortality (DcTnI: T3: 4.9% vs. T1: 0.5%, p ¼ 0.01;
DCK-MB: T3: 3.9% vs. T1: 0.5%, p ¼ 0.02) at 30 days
(Figure 1A). At 1 year, there was still a signiﬁcant
difference in rates of all-cause mortality (25.4% vs.
16.8%, p ¼ 0.02) and cardiovascular mortality
(10.3% vs. 5.0%) between the highest and the lowest
CK-MB tertiles (Figure 1B). However, there was no
longer a signiﬁcant association between a larger
periprocedural cTnI release and higher 1-year all-
cause (DcTnI: T3: 23.2% vs. T1: 18.9%, p ¼ 0.22) and
cardiovascular (DcTnI: T3: 13.0% vs. T1: 7.8%,
p ¼ 0.09) mortality. The rates of MI were very low
and were similar across tertiles for both markers
(DcTnI: p ¼ 0.60, DCK-MB: p ¼ 0.37) (Table 3).
Functional assessment and echocardiography. At 1 year,
the proportion of patients with an improvement of
more than 1 class in the New York Heart Association
(NYHA) classiﬁcation system was similar across the
tertiles for both cTnI and CK-MB (DcTnI: T3: 67.4% vs.
T1: 61.1%, p ¼ 0.28; DCK-MB: T3: 57.4% vs. T1: 65.2%,
p ¼ 0.16). Additionally, no signiﬁcant differences were
noted across the tertiles in the 6-min walk performedat 1 year (DcTnI: T3: 216.9 m vs. T1: 224.5 m, p ¼ 0.64;
DCK-MB: T3: 218.1 m vs. T1: 236.2 m, p ¼ 0.30).
In paired analyses of baseline and 1-year left ven-
tricular ejection fraction (LVEF) measurements, there
was a signiﬁcant improvement in the LVEF at 1 year in
T1 and T2 DcTnI tertiles (DcTnI: T1: 3.10%, p ¼ 0.002;
T2: 2.72%, p ¼ 0.006; T3:1.78, p ¼ 0.17) and in each
DCK-MB tertile (DCK-MB: T1:4.41%, p ¼ 0.0001; T2:
2.58%, p ¼ 0.01; T3: 2.35%, p ¼ 0.02). The degree of
cTnI or CK-MB elevation was not associated with
LVEF change (DcTnI: T3:1.78% vs. T1:3.10%, p ¼ 0.31,
DCK-MB: T3: 2.35% vs. T1: 4.41%, p ¼ 0.15).
Transap ica l approach . Mortality. There was no sig-
niﬁcant difference in all-cause or cardiovascular
mortality at 30 days or 1 year when comparing
patients in the lowest and highest tertiles (Figures 2A
and 2B). The incidence of MI at 30 days was similar
between the highest and lowest tertiles of both
biomarkers (DcTnI: T3: 1.8% vs. T1: 0.9%, p ¼ 0.56;
DCK-MB: T3: 1.5% vs. T1: 0.7%, p ¼ 0.56) (Table 3).
Functional assessment and echocardiography. At 1 year,
the fraction of individuals with improvement of the
NYHA functional classiﬁcation by more than 1 class
was similar between tertiles of both cardiac bio-
markers (DcTnI: T3: 79.5% vs. T1: 71.4%, p ¼ 0.25;
DCK-MB: T3: 72.7% vs. T1: 79.8%, p ¼ 0.26). The
6-min walk distance at 1 year was also similar
between T3 and T1 for both biomarkers (DcTnI: T3:
214.6 m vs. T1: 245.5 m, p ¼ 0.15; DCK-MB: T3: 187.7
m vs. T1: 201.1 m, p ¼ 0.49).
In paired analyses, there was no signiﬁcant change
in LVEF from baseline to 1 year in any tertile of either
cardiac biomarker (DcTnI: T1: 2.28%, p ¼ 0.06; T2:
1.32%, p ¼ 0.18; T3: -0.37%, p ¼ 0.41; DCK-MB: T1:
2.27%, p ¼ 0.09; T2: 1.74%, p ¼ 0.23; T3: -0.03%,
p ¼ 0.90) after TA-TAVR at 1 year. The degree of
myocardial injury across tertiles (T3 vs. T1) did not
inﬂuence the change in LVEF 1 year after a TA pro-
cedure (DcTnI: p ¼ 0.09, DCK-MB: p ¼ 0.18).
Multivariable analysis.Multivariable analyses were
performed to evaluate the association between a
greater release of cardiac biomarkers and increased
mortality in the TF population. After adjusting for
signiﬁcant confounders (Table 4), the highest tertile
of DcTnI and of DCK-MB remained independent
predictors of 30-day all-cause and cardiovascular
mortality. At 1 year, a higher CK-MB elevation (T3 vs.
T1) was an independent predictor of all-cause death
and of cardiac death. In the multivariable analysis,
renal disease requiring dialysis was identiﬁed as a
predictor of 1 year all-cause mortality, whereas
the incidence of major vascular complication was
linked to a higher rate of cardiovascular mortality at
12 months.
TABLE 3 Results of TF- and TA-TAVR at 30 Days and 1 Year
cTnI CK-MB
T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups) T1 T2 T3
p Value
(T1 vs. T3)
p Value
(All Groups)
Transfemoral
30 days
All-cause mortality 0.5 2.7 5.4 0.006 0.02 0.9 1.4 5.7 0.006 0.004
Cardiovascular mortality 0.5 1.6 4.9 0.01 0.02 0.5 1.4 3.9 0.02 0.03
Myocardial infarction 0 0.5 0.5 0.32 0.60 0.9 0 0.5 0.57 0.37
Days in hospital post-procedure 5.30 5.58 5.95 0.01 0.05 5.45 5.42 5.63 0.42 0.61
Stroke or TIA 3.8 3.3 7.6 0.11 0.10 1.4 4.2 7.7 0.002 0.008
Moderate or severe AR 19.2 15.4 19.4 0.97 0.57 9.2 16.5 14.5 0.11 0.09
Major vascular complications 4.8 8.7 14.0 0.002 0.009 7.1 10.4 14.9 0.01 0.04
Major bleeding 6.4 6.6 13.5 0.02 0.02 5.7 7.1 14.9 0.002 0.002
Need for dialysis 2.2 1.6 3.2 0.50 0.57 0.9 0.9 3.4 0.09 0.09
1 year
All-cause mortality 18.9 22.5 23.2 0.22 0.44 16.8 22.0 25.4 0.02 0.07
Cardiovascular mortality 7.8 6.4 13.0 0.09 0.07 5.0 8.7 10.3 0.04 0.11
Improved >1 NYHA functional class from baseline 61.1 70.5 67.4 0.28 0.24 65.2 60.6 57.4 0.16 0.37
6-min walk test, m 224.5 212.5 216.9 0.64 0.75 236.2 212.0 218.1 0.30 0.33
Change of LVEF from baseline 3.10 2.72 1.78 0.31 0.59 4.41 2.58 2.35 0.15 0.25
Transapical
30 days
All-cause mortality 6.2 4.4 7.1 0.79 0.67 6.5 5.8 12.2 0.10 0.09
Cardiovascular mortality 3.5 1.8 3.6 1.0 0.65 3.7 2.9 4.4 0.75 0.79
Myocardial infarction 0.9 0.9 1.8 0.56 0.77 0.7 0.7 1.5 0.56 0.78
Days in hospital post-procedure 6.9 7.4 7.1 0.69 0.48 6.8 7.3 7.7 0.056 0.15
Stroke or TIA 3.6 1.8 3.6 1.0 0.64 2.2 5.1 6.6 0.07 0.21
Moderate or severe AR 11.0 11.0 11.0 1.0 1.0 9.6 8.2 7.1 0.50 0.70
Major vascular complications 0 1.8 5.3 0.01 0.03 0.7 2.9 5.8 0.02 0.05
Major bleeding 5.4 4.4 11.7 0.09 0.07 4.4 7.3 8.8 0.14 0.34
Need for dialysis 2.8 3.5 7.3 0.12 0.21 7.4 1.5 3.0 0.10 0.03
1 year
All-cause mortality 21.7 18.5 28.8 0.21 0.15 23.5 23.4 28.5 0.32 0.48
Cardiovascular mortality 10.5 8.4 10.9 0.92 0.79 11.7 7.0 9.5 0.63 0.45
Improved >1 NYHA functional class from baseline 71.4 73.0 79.5 0.25 0.49 79.8 69.4 72.7 0.26 0.25
6-min walk test, m 245.5 208.6 214.6 0.15 0.15 201.1 195.6 187.7 0.49 0.78
Change of LVEF from baseline 2.28 1.32 -0.37 0.09 0.24 2.27 1.74 -0.03 0.18 0.37
Values are percentages unless otherwise indicated.
AR ¼ aortic regurgitation; TIA ¼ transient ischemic attack; other abbreviations as in Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5 Paradis et al.
S E P T E M B E R 2 0 1 5 : 1 4 6 8 – 7 9 Myocardial Injury After TAVR
1475DISCUSSION
In patients with elevated surgical risk treated with
TAVR in the PARTNER trial and reported in the NRCA
registry, post-operative cardiac biomarker elevation
was common after the procedure. Higher differences
between pre- and post-procedural CK-MB values
resulted in an increase in short-term all-cause and
cardiac mortality rates in patients undergoing trans-
femoral TAVR. Also, in the multivariable analysis, the
highest tertile of CK-MB persisted as an independent
predictor of 1-year all-cause and cardiac mortality.
The degree of myocardial injury did not inﬂuence the
improvement of NYHA class, the performance on the6-min walk test, or the change in LVEF at 1 year.
There was no association of myocardial injury with
30-day or 1-year mortality in patients undergoing
TA-TAVR as measured by changes in the cardiac
biomarkers.
Larger cardiac biomarker elevation is seen after
TA-TAVR due to instrumentation of the LV apex and
the surgical repair of the ventriculotomy. A certain
degree of myocardial injury is expected during this
procedure, resulting in higher CK-MB and cTnI
elevation, perhaps masking its prognostic value. Our
ﬁndings are similar to those reported by Barbash et al.
(7) who showed that an increase of cTnI or CK-MB had
no prognostic accuracy to predict 30-day mortality
FIGURE 2 All-Cause and Cardiovascular Mortality After TA-TAVR
Thirty-day (A) and 1-year (B) all-cause and cardiovascular mortality rates after transapical (TA)-TAVR, stratiﬁed by cardiac enzyme tertiles. Abbreviations as in Figure 1.
Continued on the next page
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1476among TA patients. In addition, there were no sta-
tistically signiﬁcant differences between tertiles for
NYHA functional class improvement, 6-min walk test
distance, or LVEF recovery at 1 year after TA-TAVR,
minimizing the importance of these laboratory
ﬁndings.
In the TF subset, cardiac biomarker elevation ap-
pears to play a role in predicting mortality. Elevation
of cTnI or CKMB after TAVR may be associated to
patient or procedural characteristics. Patients with a
higher degree of cardiac enzymes elevation were
older; more frequently female; had lower body mass
index; and lower rates of coronary artery disease,
chronic obstructive pulmonary disease, diabetesmellitus, and previous coronary artery bypass graft.
Periprocedural biomarker elevation may be due to the
presence of lower capillary density and a larger degree
of LV hypertrophy in previously unscarred ventricles.
Procedural characteristics such as procedural time;
episodes of hypotension; duration of rapid ventricular
pacing; injury by the guidewire or delivery system;
coronary obstruction; or abnormal coronary perfusion
due to elevated LV end-diastolic pressure, pre-
existing unrevascularized coronary disease, and pro-
cedural hypotension are associated with episodes
of ventricular ischemia. Yong et al. (13) identiﬁed
procedural duration as an independent predictor of
myocardial injury after TAVR with the Medtronic
FIGURE 2 Continued
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1477CoreValve device (Minneapolis, Minnesota). In our
analysis with the Edwards Sapien transcatheter heart
valve, procedural time was longer in the highest ter-
tiles of DcTnI and DCK-MB after TF cases only. Longer
cases are also associated with procedural complica-
tions that may further predispose to myocardial
ischemia. Depth of implantation has also been iden-
tiﬁed as a risk factor for periprocedural myocardial
damage in patients undergoing self-expanding TAVR,
but this ﬁnding may apply to patients undergoing
TAVR with a balloon-expanding prosthesis.
Numerous studies have demonstrated that the
occurrence of myocardial injury after a cardiac pro-
cedure such as cardiac surgery or percutaneous cor-
onary intervention is correlated with worse future
cardiovascular outcomes (14,15). Nevertheless, thereis a paucity of data on the impact of myocardial injury
following TAVR. Following a TF procedure, Buelles-
feld et al. (16) and Grube et al. (17) have reported an
incidence of 1.5% to 1.8% of CK-MB elevation >2 the
upper limit of normal. Using the deﬁnition of spon-
taneous myocardial infarction, Svensson et al. (18)
demonstrated that periprocedural MI occurred in
17% of patients who underwent a TA procedure. The
study by Rodés-Cabau et al. (5) showed that uncom-
plicated TAVR was associated with some degree of
troponin elevation in 99% of patients. In our study,
the presence of biomarker elevation was associated
with mortality in the TF patients even in levels that
were not considered diagnostic for MI. In these
high-risk patients, the extent of comorbidities may
suggest a lower threshold of injury required to be
TABLE 4 Multivariable Analysis for 30-Day and 1-YearMortality Rates
HR 95% CI p Value
30 days
All-cause mortality
DcTnI T3 vs. T1 10.21 1.31–79.79 0.03
DCK-MB T3 vs T1 6.20 1.39–27.71 0.02
Cardiovascular mortality
DcTnI T3 vs. T1 9.20 1.17–72.61 0.04
DCK-MB T3 vs. T1 8.24 1.03–65.83 0.04
1 year
All-cause mortality
DCK-MB T3 vs. T1 1.62 1.06–2.49 0.02
Renal disease—dialysis
required
1.59 1.06–2.39 0.02
Cardiovascular mortality
DCK-MB T3 vs. T1 2.21 1.03–4.72 0.04
LVEF 0.97 0.95–0.99 0.001
Major vascular
complication
3.07 1.55–6.08 0.001
The following variables were included in the multivariable analysis: DcTnI; DCK-
MB; age; STS score; LVEF at baseline; major vascular complication; and renal
failure (dialysis required).
CI¼ conﬁdence interval; HR¼ hazard ratio; otherabbreviations as inTables 1 and2.
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1478considered pathologic. Furthermore, it is possible
that the degree of coronary reserve is lower in these
patients, which may predispose to procedural
myocardial damage.
In another study (5), the TA approach and baseline
renal insufﬁciency were the main predictors of a
greater increase in cardiac biomarkers levels. Indeed,
cardiac mortality at 9-month follow-up was higher in
patients with a larger rise in cardiac troponin level. A
greater degree of myocardial injury was linked with a
reduced improvement of LVEF. In our study, patients
in the highest CK-MB tertile had a signiﬁcantly higher
cardiovascular mortality at 12 months and only pa-
tients in the highest tertile of delta troponin did not
signiﬁcantly improve their LVEF after TF-TAVR. On
the contrary, all the patients who underwent a TA
procedure had no signiﬁcant modiﬁcation of their
LVEF at 1 year, regardless of the degree of cardiac
biomarker elevation.
Renal dysfunction can be interrelated with higher
levels of cardiac troponin even in the absence of clin-
ically suspected myocardial ischemia (19). In the study
by Carrabba et al. (6), TAVR was systematically asso-
ciated with myocardial injury, occurring at a greater
level in individuals who developed acute kidney
injury. However, in our analysis, all tertiles of cTnI,
after both TF and TA procedures, were associated with
similar rates of 30-day need for dialysis. Nonetheless,
in the multivariable analysis, post-procedural renal
failure requiring dialysis was still identiﬁed as an in-
dependent predictor of 1-year all-cause mortality.STUDY LIMITATIONS. The PARTNER trial was per-
formed using ﬁrst-generation devices (22- and 24-F
sheath introducer diameter for the TF approach and
29-F for the TA route) with operators and sites at the
beginning of their learning curve. The evolution to-
ward lower proﬁle TAVR devices might affect the
level of myocardial damage after TAVR, especially for
TA cases. Moreover, different reference values of
biomarkers measured created the need to analyze the
data in tertiles using each patient as his/her own
control. Furthermore, to decrease the variability
associated with the use of multiple troponin assays,
only patients with available TnI measurements have
been included in our analysis. Consequently, the
number of patients included was reduced, therefore
affecting the power to detect signiﬁcant differences
between tertiles. Also, the delta was calculated
only with the 24-h post-procedural value. Because
troponin is known to peak around 48 h post-TAVR (5),
the calculation used in our analysis might have
underestimated the maximal delta in a certain num-
ber of patients. To establish the exact location and the
precise amount of myocardial injury, cardiac mag-
netic resonance imaging after TAVR could have been
a useful imaging modality. In addition, the small
number of clinical adverse events allowed the
adjustment for very few covariates, subsequently
limiting the multivariable analysis. Finally, other
potential, unmeasured confounders may still be
present, and this post-hoc secondary analysis of
data collected as part of a randomized trial should
be considered hypothesis-generating rather than
deﬁnitive.
CONCLUSIONS
Our study, which is the largest published to date on
the topic of cardiac biomarker elevation after TAVR,
demonstrates that after TF-TAVR, a higher elevation
of cTnI is associated with higher frequencies of 30-day
all-cause and cardiovascular mortality. A greater rise
of CK-MB after TF-TAVR is correlated with increased
rates of 30-day and 1-year all-cause and cardiovascu-
lar mortality. The degree of myocardial injury after
TA-TAVR had no inﬂuence on short- and long-term
survival. Further studies are needed to elucidate the
patient and procedural factors that contribute to
greater myocardial injury during TAVR so that steps
can be taken to address those that are modiﬁable.
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PERSPECTIVES
WHAT IS KNOWN? TAVR has become the standard
treatment option for inoperable patients with severe
symptomatic aortic stenosis and has been shown to be
noninferior to surgical AVR in terms of survival among
selected high-risk patients. Recent studies have demon-
strated that TAVR is systematically associated with some
degree of myocardial injury. The exact clinical signiﬁcance
of cardiac biomarker elevation after TAVR remains
uncertain.
WHAT IS NEW? Our study, which is the largest pub-
lished to date on the topic of cardiac biomarker elevation
after TAVR, demonstrates that after TF-TAVR, a higher
elevation of cTnI is associated with higher rates of 30-day
all-cause and cardiovascular mortality. A greater rise of
CK-MB after TF-TAVR is correlated with increased fre-
quencies of 30-day and 1-year all-cause and cardiovas-
cular mortality. The degree of myocardial injury after TA-
TAVR had no impact on short- and long-term survival.
WHAT IS NEXT? Further studies will be needed not only
to substantiate the inﬂuence of cardiac biomarker eleva-
tion on outcomes after TAVR, especially with newer
generation devices, but also to identify precautionary
actions that could reduce the amount of myocardial injury
after TAVR.
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